21 Sep 2020

Investing in Form-Fill-Seal technology

PDF 82 kB

Extensive process understanding is required to ensure the consistent manufacture of high-quality sterile parenteral products. At Grifols, our use of state-of-the-art automated aseptic processing systems, including form-fill-seal (FFS) technology, ensures control with minimal human intervention.

Content provided by our supplier

Grifols International, S.A.

  • ES
  • 2015
    On CPHI since
  • 4
  • 5000+
Company types
Contract Service
Primary activities
Contract Manufacturer
Custom Manufacturing/Custom Synthesis

Other Content from Grifols International, S.A. (9)

  • Brochure Grifols Partnership - Parenterals CDMO - Flyer

    Grifols Partnership is a contract development and manufacturing platform (CDMO) focused on added value injectable products, with a large, international experience in the development and manufacturing of many types of sterile drug products. We specialize in small molecule intravenous solutions and offer high quality pharmaceutical development and product manufacturing. Our portfolio also includes products which require careful design and assembly, including medical devices and bags for blood storage and collection.
  • Brochure Grifols Partnership - Parenterals CDMO

    Brochure describing Grifols Partnership services, products and capabilities offered to pharmaceutical companies. Featuring two FDA approved Manufacturing sites
  • Brochure Grifols Partnership - Vial filling

    Grifols Partnership: your CMO for filling vials. Because diluent is as important as your API
  • Brochure Rare specialist for tomorrow's medicines

    Rare specialist for tomorrow's medicines
  • Whitepaper Supporting Small and emerging pharma through collaboration and specialized expertise

    Growth in the pharmaceutical industry is no longer exclusively driven by large pharmaceutical companies. The switch in the marketplace from a focus on blockbuster drugs to an emphasis on therapies that treat orphan and rare diseases has led to the rise of small and emerging pharma companies founded to advance novel medicines for specialized patient populations. These innovators require the support of contract service providers that recognize their unique requirements.
  • Whitepaper Catering to a growing demand for Small-volume parenteral manufacturing

    Drug candidates are becoming increasingly complex as manufacturers continue to focus on niche and personalized medicines. Contract development and manufacturing organizations with process and capacity, flexibility, and wide-ranging expertise in small-volume GMP manufacturing are needed to support efforts by pharma companies to rapidly bring these specialized products to the market.
  • Whitepaper Trends shaping the dynamic market for parenterals

    Demand for parenteral drugs continues to increase as the overall drug market expands and new therapies for both chronic and rare diseases enter the pipeline. Manufacturers are faced with increasing complexity, not only because of the drug substances, but also due to formulations, patient-centric delivery technologies,and regulatory requirements, which are all further complicated by abbreviated development timelines.
  • Whitepaper The critical role of continous improvement in parenteral drug manufacturing

    In the competitive pharmaceutical manufacturing landscape, the ability to continuously achieve improvements in efficiency and productivity is essential to success. Given the higher complexity of parenteral drug manufacturing, continuously improving production processes is also paramount for ensuring the highest level of quality.
  • Video Grifols Partnership - Company presentation

    Grifols Partnership is a business to business contract development and manufacturing platform for sterile solutions (small molecules) with over 75 years of experience in producing high-quality intravenous solutions for the pharmaceutical industry worldwide.

    Watch our video and learn more about our contract manufacturing services.